For the quarter ending 2026-03-31, NAMS has $732,643K in assets. $67,421K in debts. $457,607K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 457,607 | 490,002 | 538,407 | 563,864 |
| Prepayments and other receivables | 20,603 | 38,138 | 28,074 | 30,688 |
| Marketable securities, current | 178,498 | 146,239 | 164,539 | 175,298 |
| Restricted cash | 1,336 | 1,321 | 1,308 | - |
| Total current assets | 658,044 | 675,700 | 732,328 | 769,850 |
| Marketable securities, net of current portion | 71,239 | 92,609 | 53,091 | 44,172 |
| Property, plant and equipment, net | 379 | 383 | 323 | 312 |
| Operating right of use asset | 21 | 185 | 246 | 308 |
| Intangible assets | 375 | 407 | 439 | 470 |
| Long term prepaid expenses | 2,585 | - | - | - |
| Total assets | 732,643 | 769,284 | 786,427 | 815,112 |
| Accounts payable | 8,090 | 8,970 | 3,632 | 5,895 |
| Accrued expenses and other current liabilities | 5,092 | 15,422 | 10,098 | 9,460 |
| Deferred revenue, current | 3,987 | 3,987 | - | - |
| Lease liability, current | 23 | 136 | 181 | 225 |
| Derivative warrant liabilities | 50,229 | 57,272 | 44,361 | 20,932 |
| Total current liabilities | 67,421 | 85,787 | 58,272 | 36,512 |
| Lease liability, net of current portion | - | 66 | 85 | 103 |
| Total liabilities | 67,421 | 85,853 | 58,357 | 36,615 |
| Ordinary shares | 14,594 | 14,278 | 14,107 | 14,014 |
| Additional paid-in capital | 1,457,238 | 1,426,750 | 1,396,790 | 1,375,618 |
| Accumulated loss | -810,831 | -762,390 | -687,467 | -615,462 |
| Accumulated other comprehensive income | 4,221 | 4,793 | 4,640 | 4,327 |
| Total shareholders' equity | 665,222 | 683,431 | 728,070 | 778,497 |
| Total liabilities and shareholders' equity | 732,643 | 769,284 | 786,427 | 815,112 |
NewAmsterdam Pharma Co N.V. (NAMS)
NewAmsterdam Pharma Co N.V. (NAMS)